Copaxone

Indicated For

relapsing forms of multiple sclerosis (MS)

About This Medication

# Teva Assistance Programs Patient Guide: How to Get Copaxone (glatiramer acetate) at Low or No Cost Copaxone (glatiramer acetate) is a prescription injection used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.[2] This guide explains Teva's patient assistance options, including the **COPAXONE Co-Pay Solutions®** program for commercially insured patients and the **Teva Cares Foundation Patient Assistance Program** for uninsured or underinsured patients meeting income criteria, helping you access this important MS therapy at low or no cost.[1][3][4] ## About Copaxone and Why Assistance Matters **Copaxone** works by modulating the immune system to reduce the frequency of MS relapses and delay disease progression. It comes in two main doses: 20 mg/mL daily or 40 mg/mL three times a week (injections at least 48 hours apart), often using a compatible autoinjector.[1][6] MS treatments like Copaxone can be expensive, with costs running thousands per month without help. Teva, the manufacturer, offers programs through **Teva Shared Solutions®** and the independent **Teva Cares Foundation** to make it affordable. These include co-pay cards reducing out-of-pocket costs to $0 for eligible patients and free medication for those who qualify based on income and insurance status.[1][3][5] Thousands of patients have accessed Teva medications through these programs, ensuring cost isn't a barrier to treatment.[3] Note that generics like Glatopa (glatiramer acetate) may be available at 20-40% lower cost with similar assistance options.[9] ## Who Qualifies for Teva's Copaxone Assistance? Teva offers two main paths: 1. **COPAXONE Co-Pay Solutions®**: Best for **commercially insured** patients (private insurance, not government programs). No income check or paperwork needed. New prescriptions may qualify for a co-pay card covering up to $9,200 annually (through 12/31/2026), potentially $0 copay per fill.[1][6][8] 2. **Teva Cares Foundation PAP**: For **uninsured, underinsured, or those without prescription coverage** who meet **income criteria** (typically up to 400-500% of the Federal Poverty Level, reviewed individually) and U.S. residency. Provides free Copaxone for up to one year.[3][4][7] Medicare patients can't use the co-pay card but may get grants from independent 501(c)(3) nonprofits (up to 12 months).[1] Each case is evaluated individually.[7] ## Income Eligibility Breakdown The **Co-Pay Solutions®** has **no income limits**. For **Teva Cares Foundation**, eligibility is based on income, insurance, and other factors (exact FPL % not specified; call for details). Proof of income may be required.[4][7] Here's a general guide based on typical PAP standards (confirm with Teva): | Household Size | Annual Income Limit (est. 400% FPL, 2026) | Notes | |---------------|-------------------------------------------|-------| | Individual | ~$60,000 | Varies; individual review [4][7] | | Couple | ~$81,000 | U.S. residents only [3] | | Family of 3 | ~$102,000 | No fees for application/delivery [4] | | Family of 4 | ~$123,000 | Employer plans restricting PAPs ineligible [4] | *These are estimates; Teva Cares reviews household income, assets, and insurance. Call 877-237-4881 (M-F, 9AM-8PM ET) for exact thresholds.*[4] ## Insurance Requirements - **Co-Pay Solutions®**: **Commercial insurance required** (not Medicare, Medicaid, VA, TRICARE, etc.). Can't combine with other offers. Provide insurance/prescription/income info at enrollment.[1][10] - **Teva Cares PAP**: **Limited/no prescription coverage**. No participation in alternative funding programs requiring PAP application. Medicare patients directed to nonprofits.[1][4] - **Medicare/VA**: Use independent grants; contact nonprofits directly.[1] ## Step-by-Step Application Process ### For Co-Pay Solutions® (Easiest for Commercial Insurance): 1. Visit **COPAXONEsavingscard.com** or call **1-844-308-7007** with your insurance card, prescription, and income info.[1][10] 2. Check eligibility instantly (no paperwork).[1] 3. Get digital/physical co-pay card for pharmacy use on new fills/refills.[1][6] 4. Present card at pharmacy; pay $0 (up to annual max).[1] ### For Teva Cares Foundation PAP (Free Drug): 1. Visit **tevacares.org** or call **877-237-4881** (M-F, 9AM-8PM ET) to check medicines list/eligibility.[4] 2. Download/fill application (patient completes financial/insurance section; doctor signs).[3][7] 3. Submit with proof of income/residency to address on form (e.g., Shared Solutions, Kansas City, MO).[7] 4. Approval: Free meds shipped (no fees).[4] ### For Medicare/Grants: 1. Contact 501(c)(3) nonprofits listed on copaxone.com.[1] 2. Apply per their rules; provide approval to pharmacy.[1] **Shared Solutions®** (1-800-887-8100) offers personalized help, pharmacy location, and insurance research.[5][7] ## Timeline and Delivery - **Co-Pay Card**: Instant eligibility; use immediately at pharmacy. Max $9,200/year, ends 12/31/2026.[6] - **Teva Cares PAP**: Processing 2-4 weeks (individual review); meds shipped directly (1-year supply).[3][7] - **Grants**: Varies by nonprofit; typically 12 months.[1] Refills: Co-pay card auto-renews; PAP requires reapplication yearly.[1][7] Delivery via mail/pharmacy; autoinjectors separate if available.[6] ## Alternatives if Denied or Ineligible - **Switch to generics** (glatiramer acetate 20/40 mg/mL): Cheaper; similar co-pay help via QuickRx or others.[9] - **Nonprofits**: Medicare patients apply for grants.[1] - **Other Teva resources**: Call 888-TEVA USA (838-2872).[3] - **RxResource.org** or QuickRx for navigation.[7][9] ## Disclaimer This guide is for informational purposes based on publicly available data as of 2026. Programs change; **always verify with Teva/Shared Solutions (1-800-887-8100), tevacares.org, or copaxone.com**. Not medical/financial advice. Terms apply; Teva reserves eligibility rights. Consult your doctor. ~950 words.

Program information last verified: March 30, 2026